Back to results
US 12,247,086 B2Granted
Enhanced immunogenicity for GPI-anchored antigens
AssigneeNantBio, Inc.
InventorsKayvan Niazi, Wael Tadros, Annie Shin
Life of this patent
Estimating the term…
Abstract
Compositions and methods are presented that allow for an enhanced immune response against a GPI-anchored tumor associated antigen by modification of the protein portion of the TAA to include a transmembrane domain and a trafficking signal that directs the modified protein to the endosomal or lysosomal compartment. Most preferably, the modified protein will no longer have a GPI anchor or GPI attachment sequence.
Claims18
A recombinant nucleic acid, comprising:
- a sequence segment encoding a hybrid protein, wherein the hybrid protein comprises an antigen coupled to at least one transmembrane domain and a trafficking element;
- wherein the antigen is a glycophosphatidylinositol (GPI)-anchored protein CEA (carcinoembryonic antigen), and wherein the GPI anchor signal sequence is removed or modified to abolish or render GPI binding less efficient;
- wherein the transmembrane domain is defined by SEQ ID NO:5;
- wherein the trafficking element is CD1a (Cluster of Differentiation 1a), CD1c (Cluster of Differentiation 1c), or Lamp1 (Lysosome-associated membrane glycoprotein 1), and directs the recombinant hybrid protein to a sub-cellular location selected from the group consisting of a recycling endosome, a sorting endosome, and a lysosome;
- and
- wherein the sequence segment is operably linked to a promoter to drive expression of the hybrid protein.
3 more elements
Dependencies are inferred from the claim text.